Gavin Screaton

Head Medical Sciences Division, Dean of Medicine

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gavin Screaton is the Head of the Medical Sciences Division and Dean of Medicine at the University of Oxford, UK. His research focuses on the immune response to mRNA vaccines, antibody dynamics against SARS-CoV-2 variants, and the engineering of bacterial cells for viral neutralization. He has recently contributed to studies that explore the mechanisms of viral neutralization and the effectiveness of various COVID-19 vaccines, emphasizing the importance of antibody avidity and immunogenicity.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (28)

Mikhail Kutuzov

University of Oxford

UNITED KINGDOM

Gavin Screaton

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation.

The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Improving the representativeness of UK’s national COVID-19 Infection Survey through spatio-temporal regression and post-stratification

Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.

Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers.

Concerted deletions eliminate a neutralizing supersite in SARS-CoV-2 BA.2.87.1 spike.

Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam.

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

Accelerating drug target inhibitor discovery with a deep generative foundation model

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.

Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Collaborators (28)

Mikhail Kutuzov

Thomas House

Susanna Dunachie

Nicole Stoesser

Lee-Jah Chang

David Eyre

Lucas Rudden

Donal Skelly

Tiong Kit Tan

Christopher Schofield

Nicole Zitzmann

Philippa Matthews

Barbara Kronsteiner-Dobramysl

Stephanie Hatch

Scarlett Strickland

Tanya Golubchik

Michelle Hill

paul klenerman

Chang Liu

Xinxue Liu

Elizabeth Ann Clutterbuck

Sagida Bibi

Adriana Tomic

Ali Amini

Samuel Isaacson

Lance Turtle

John Norman Newton

Andrew Hogan

Make your next move.